Extracted from this filing and checked against the source text.
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Kinnate Biopharma Inc. completed a disposition involving Pierre Fabre Médicament, SAS for up to $31.0 million, consisting of $500,000 at closing (closed 2024-02-27).
- Action
- disposition
- Counterparty
- Pierre Fabre Médicament, SAS
- Consideration
- up to $31.0 million, consisting of $500,000 at closing
- Closing
- 2024-02-27
Exact text from the filing
exarafenib and other pan-RAF assets and will assume 100% of the ongoing program and costs associated with these assets. The Company will receive a total consideration of up to $31.0 million, consisting of $500,000 at closing, and an additional $30.5 million contingent upon the earlier of (i) the dosing of the first patient in the first pivotal trial for exarafenib
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Kinnate Biopharma Inc. entered into Purchase Agreement with Pierre Fabre Médicament, SAS valued at up to $31.0 million (effective 2024-02-27).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- Pierre Fabre Médicament, SAS
- Value
- up to $31.0 million
- Effective
- 2024-02-27
Exact text from the filing
On February 27, 2024, Kinnate Biopharma Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) by and among the Company and Pierre Fabre Médicament, SAS (“Pierre Fabre”), pursuant to which it sold the global rights to its investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets to Pierre Fabre, subject to the terms and conditions of the Purchase Agreement.
View on SEC.gov